Pfizer submits supplemental Prevnar 13 apps; Intercell launches C. diff vaccine trial

Vaccine Market

Pfizer has submitted supplemental applications to the FDA and the EMA to expand the use of Prevnar 13 to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine. Release

Chinese officials have dispatched eight people to prison after accusing them of selling a fake rabies vaccine. Story

Canadian health officials say they want to learn how to avoid repeating the kind of snafus that afflicted their response to the swine flu pandemic. Report

Vaccine Research

Intercell AG has launched an early-stage study of a new vaccine to guard against disease caused by the Clostridium difficile or C. difficile. Release

Medicago says investigators have completed the first part of its Phase II human clinical trial with its H5N1 Avian Influenza vaccine. The company expects to present interim Phase II clinical trial results with its H5N1 pandemic influenza vaccine in January, 2011. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.